Agilent Technologies, Inc. (NYSE: A - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen research firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to

Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in Agilent Technologies, Inc. (NYSE: A) by 288.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,463 shares of the medical research company's stock after acquiring an additional 9,258

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea.

Agilent (A) reported earnings 30 days ago. What's next for the stock?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica.

Nordea Investment Management AB lessened its stake in Agilent Technologies, Inc. (NYSE: A) by 5.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,774,119 shares of the medical research company's stock after selling 106,321 shares during the period. Nordea Investment Management AB

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a founda.

Danske Bank A S bought a new position in shares of Agilent Technologies, Inc. (NYSE: A) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 401,467 shares of the medical research company's stock, valued at approximately $51,528,000. Danske Bank A S owned approximately

Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript

Aquatic Capital Management LLC reduced its position in Agilent Technologies, Inc. (NYSE: A) by 43.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 53,601 shares of the medical research company's stock after selling 41,359 shares during the period. Aquatic Capital Management LLC's holdings in